Poseida Therapeutics Inc Collaboration and Poseida's Novel Approach to Allogeneic Cell Therapy - Corporate Call Transcript
Welcome to Poseida Therapeutics' investor call. Thank you for joining us for today's presentation. My name is Gretchen, and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being recorded and that there will be no Q&A following this presentation.
Presenting today is Poseida's CEO, Mark Gergen. Earlier this morning, Poseida issued a press release announcing its strategic global collaboration with Roche, focused on utilizing Poseida's proprietary platform technologies to develop allogeneic CAR-T-cell therapy for hematologic malignancies. Poseida encourages everyone to read today's press release and the associated materials which have been filed with the SEC. Additionally, the press release presentation and recording on this website can be found under the Investors section of the company's website at www.poseida.com
Please note that certain information discussed on today's call contains forward-looking statements within the meaning of the Private Securities Litigation
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |